ArticleMolecular and clinical oncology2026
Exploring the value of the ovarian-adnexal reporting and data system combined with tumor markers in the differential diagnosis of benign and malignant ovarian-adnexal tumors.
Article in Molecular and clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the value of the ovarian-adnexal reporting and data system (O-RADS) combined with tumor markers, risk of ovarian malignancy algorithm (ROMA) in the differential diagnosis of benign and malignant ovarian-adnexal tumors. A total of 426 patients with 524 cases of ovarian-adnexal tumors confirmed by surgery from January 2021 to January 2024 were included. Ultrasound O-RADS classification, ROMA and their combination were used for differential diagnosis. Taking pathological results as the gold standard, the sensitivity, specificity and the area under the receiver operating characteristic curves were calculated. Among the 524 tumors, there were 104 cases in category 2, 113 cases in category 3, 81 cases in category 4, 226 cases in category 5. The proportions of malignancy in O-RADS categories 2-5 were 0% (0/104), 4.42% (5/113), 53.09% (43/81) and 97.34% (220/226). Thus, it can be observed that the higher the ultrasound O-RADS classification, the higher the risk of malignancy. This was statistically significant. Taking O-RADS category 4 as the research objective, the patients were divided into two groups, pre-menopausal and post-menopausal for statistical analysis. Analysis revealed that the malignancy rate of postmenopausal O-RADS category 4 tumors was similar to that of O-RADS category 5. The risk of malignant tumors in postmenopausal women with O-RADS category 4 is significantly higher compared with that in premenopausal patients and the difference is statistically significant. The diagnostic efficacy of ROMA for benign and malignant tumors in postmenopausal patients was significantly greater when compared with premenopausal patients. When combined diagnosis is adopted, regardless of whether it is in the premenopausal or postmenopausal stage, the sensitivity and specificity of the diagnosis are significantly higher compared with those of a single diagnosis. Taking O-RADS category 4 as the research objective, the incidence of malignant tumors of O-RADS category 4 in postmenopausal women is similar to that of category 5. The diagnostic efficacy of ROMA for postmenopausal patients is greater when compared with that for premenopausal patients. The use of O-RADS classification combined with ROMA can improve the sensitivity and specificity for the differential diagnosis of benign and malignant ovarian-adnexal tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.